B Testa1, M Reist, P A Carrupt
1Institut de chimie thérapeutique, BEP, Université de Lausanne, CH-1015 Lausanne-Dorigny. Bernard.Testa@ICT.UNIL.CH.
Chiral drugs present unique challenges in research and development due to differing enantiomer properties. Understanding pharmacokinetic interactions and configurational stability is crucial for effective drug design and selection between single enantiomers or racemates.
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Area of Science: